83402-63-5

Basic information

• Product Name: 2-(Indan-2-ylamino)acetic acid tert-butyl ester
• Synonyms: 2-(Indan-2-ylamino)acetic acid tert-butyl ester;N-(2,3-Dihydro-1H-inden-2-yl)glycine 1,1-dimethylethyl ester
• CAS NO: 83402-63-5
• Molecular Formula: C₁₅H₂₁NO₂
• Molecular Weight: 0
• Mol File: 83402-63-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(Indan-2-ylamino)acetic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Indan-2-ylamino)acetic acid tert-butyl ester(83402-63-5)
• EPA Substance Registry System: 2-(Indan-2-ylamino)acetic acid tert-butyl ester(83402-63-5)

Safety Data

• Hazardous Substances Data: 83402-63-5(Hazardous Substances Data)

Usage

Common uses

Organic synthesis, pharmaceutical research

Ester derivative

2-(indan-2-ylamino)acetic acid

Potential application

Antihypertensive agent

Tert-butyl ester group

Increased stability and solubility

Value

Valuable intermediate in the synthesis of various pharmaceuticals and organic compounds

Indan-2-ylamino group

Exhibits a range of biological activities, including potential antihypertensive and vasodilatory effects

Significance

Potential for further research and development in medicinal chemistry

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 2338-18-3 2-aminoindane hydrochloride 
• 584-08-7 potassium carbonate 
• 71666-98-3 tert-butyl glycinate hydrophosphite 
• 615-13-4 2-indanone 
• 2975-41-9 2,3-dihydro-1H-inden-2-amine 

Downstream Products

• 105259-82-3 tert-butyl N--L-alanyl>-N-(2-indanyl)glycinate 
• 83435-61-4 N-(2,3-dihydro-1H-inden-2-yl)-N--L-alanyl>-glycine t-butyl ester 
• 83398-08-7 Delaprilat 
• 83435-67-0 delapril hydrochloride 
• 108428-40-6 N--L-alanyl>-N-(indan-2-yl)glycine 
• 83435-62-5 N--L-alanyl>-N-(indan-2-yl)glycine 
• 83435-63-6 N--L-alanyl>-N-(indan-2-yl)glycine 
• 101820-31-9 N-(2,3-dihydro-1H-inden-2-yl)-N--L-alanyl>glycine hydrochloride 
• 105259-81-2 tert-butyl N--L-alanyl>-N-(2-indanyl)glycinate 
• 83435-60-3 N--L-alanyl>-N-(indan-2-yl)glycine tert-butyl ester 
• 83402-67-9 N-(N-benzyloxycarbonyl-L-alanyl)-N-(2-indanyl)glycine tert-butyl ester 

Relevant articles and documents

Continuous Flow Synthesis of ACE Inhibitors From N-Substituted l-Alanine Derivatives

A strategy for the continuous flow synthesis of angiotensin converting enzyme (ACE) inhibitors is described. An optimization effort guided by in situ IR analysis resulted in a general amide coupling approach facilitated by N-carboxyanhydride (NCA) activation that was further characterized by reaction kinetics analysis in batch. The three-step continuous process was demonstrated by synthesizing 8 different ACE inhibitors in up to 88 % yield with throughputs in the range of ≈0.5 g h?1, all while avoiding both isolation of reactive intermediates and process intensive reaction conditions. The process was further developed by preparing enalapril, a World Health Organization (WHO) essential medicine, in an industrially relevant flow platform that scaled throughput to ≈1 g h?1.

Design and synthesis of N-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-N-(indan-2-y l)glycine (CV-3317), a new, potent angiotensin converting enzyme inhibitor

-

Angiotensin-Converting Enzyme Inhibitors. New Orally Active Antihypertensive (Mercaptoalkanoyl)- and glycine Derivatives

A variety of N-substituted (mercaptoalkanoyl)- and glycine derivatives was synthesized and their ability in inhibiting the activity of angiotensin-converting enzyme (ACE) was examined in vitro and in vivo.The acylthio derivatives prepared are assumed to act as prodrugs since they are much less active than the corresponding free SH compounds in vitro and can be expected to act in vivo only after conversion to the free sulfhydryl compounds.A number of this compounds are potent ACE inhibitors that lowered blood pressure in Na-deficient, conscious spontaneously hypertensive rats (SHR), a high renin model.One of the most active members of the series was (S)-N-cyclopentyl-N--2-methyl-1-oxopropyl>glycine (REV 3659-(S), pivopril).Structure-activity relationships are discussed.